Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.

Front Pharmacol · 2022 · PMC9354395 · PMID 35935821

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly significantno p-value reported

One-way sensitivity analysis showed that changes in health utility values had only a slightly significant effect on the model.

also in 1,756 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.